Guy's and St. Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, United Kingdom; and
Lymphoma Study Association-Imaging (LYSA-IM), Functional Imaging and Therapeutics Department, Henri Mondor University Hospitals, University Paris Est Créteil, Créteil, France.
J Nucl Med. 2019 Aug;60(8):1096-1102. doi: 10.2967/jnumed.119.227249. Epub 2019 Apr 6.
Increased tumor burden is associated with inferior outcomes in many lymphoma subtypes. Surrogates of tumor burden that are easy to measure, such as the maximum tumor dimension of the bulkiest lesion on CT, have been used as prognostic indices for many years. Recently, total metabolic tumor volume (MTV) and tumor lesion glycolysis have emerged as promising and robust biomarkers of outcome in various lymphomas. The median MTV and the optimal cutoffs to separate patients into risk groups in a study population are, however, highly dependent on the population characteristics and the delineation method used to outline tumor on the PET image. This issue has precluded the use of MTV for risk stratification in trials and clinical practice. Standardization of the methodology is timely to allow the potential for risk adaptation to be explored in addition to response adaptation using PET. Meetings between representatives from research groups active in the field were held under the auspices of the PET International Lymphoma and Myeloma Workshop. A summary of those discussions, which included a review of the literature and a practical assessment of methods used for outlining, including various software options, is presented. Finally, a proposal is made to perform a technical validation of MTV measurement enabling benchmark reference ranges to be derived for published delineation approaches used for outlining with various software. This process would require collation of representative imaging data sets of the most common lymphoma subtypes; agreement on pragmatic criteria for the selection of lesions; generation of a range of MTVs, with consensus to be reached on final contours in a training set; and development of automated software solutions with a set of minimum functionalities to reduce measurement variability. Methods developed in the above training exercise could then be applied to another data set, with a final set of contours and values generated. This final data set would provide a benchmark against which end-users could test their ability to measure MTVs that are consistent with expected values. The data set and automated software solutions could be shared with manufacturers with the aim of including these in standard workflows to allow standardization of MTV measurement across the world.
在许多淋巴瘤亚型中,肿瘤负担的增加与较差的预后相关。多年来,易于测量的肿瘤负担替代物(如 CT 上最肿大病变的最大肿瘤直径)一直被用作许多预后指标。最近,总代谢肿瘤体积(MTV)和肿瘤病变糖酵解已成为各种淋巴瘤中具有前景和强大的预后生物标志物。然而,在研究人群中,中位数 MTV 以及将患者分为风险组的最佳截断值高度依赖于人群特征和用于勾画 PET 图像上肿瘤的方法。这个问题使得 MTV 无法用于临床试验和临床实践中的风险分层。为了除了使用 PET 进行反应适应性之外,还能够探索风险适应性,因此及时对方法进行标准化是必要的。在 PET 国际淋巴瘤和骨髓瘤研讨会的主持下,召开了代表该领域活跃研究小组的会议。会议总结了讨论内容,包括对文献的回顾以及对勾画方法的实际评估,包括各种软件选项。最后,提出了对 MTV 测量进行技术验证的建议,以便为使用各种软件进行勾画的已发表勾画方法导出基准参考范围。这个过程需要收集最常见淋巴瘤亚型的有代表性的成像数据集;就选择病变的实际标准达成一致;生成一系列 MTV,并在训练集中就最终轮廓达成共识;开发具有一套最小功能的自动软件解决方案,以减少测量的可变性。然后,可以将在上述培训练习中开发的方法应用于另一个数据集,生成最终的轮廓和值。该最终数据集将提供一个基准,用户可以使用该基准测试他们测量 MTV 的能力,这些 MTV 与预期值一致。数据集和自动软件解决方案可以与制造商共享,目的是将这些解决方案纳入标准工作流程中,以实现全球范围内 MTV 测量的标准化。